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Abstract
Evidence has shown that lymphatic drainage contributes to removal of debris from the brain but its 
role in the accumulation of amyloid β peptides (Aβ) has not been demonstrated. We examined the 
levels of various forms of Aβ in the brain, plasma and lymph nodes in a transgenic model of 
Alzheimer’s disease (AD) at different ages. Herein, we report on the novel finding that Aβ is 
present in the cervical and axillary lymph nodes of AD transgenic mice and that Aβ levels in 
lymph nodes increase over time, mirroring the increase of Aβ levels observed in the brain. Aβ 
levels in lymph nodes were significantly higher than in plasma. At age 15.5 months, there was a 
significant increase of monomeric soluble Aβ40 (p=0.003) and Aβ42 (p=0.05) in the lymph nodes 
over the baseline values measured at 6 months of age. In contrast, plasma levels of Aβ40 showed 
no significant changes (p=0.68) and plasma levels Aβ42 significantly dropped (p=0.02) at the 
same age. Aβ concentration was low to undetectable in splenic lymphoid tissue and several other 
control tissues including heart, lung, liver, kidneys and intestine of the same animals, strongly 
suggesting that Aβ peptides in lymph nodes are derived from the brain.
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Introduction
Amyloid accumulation in senile plaques is the main neuropathological feature of 
Alzheimer’s disease (AD); however, the mechanisms underlying its age-related 
accumulation remain elusive. Amyloid fibrils are composed of a 40–42 amino acid peptide 
called the amyloid beta protein (Aβ) (Glenner and Wong, 1984; Masters et al., 1985). 
Inadequate clearance of Aβ from the brain is considered to play an important role in amyloid 
accumulation (Neve and Robakis, 1998; Sambamurti et al., 2011). Prior research has 
demonstrated that peripheral lymph nodes participate in immune-surveillance and antigen 
presentation in the brain, particularly during neuro-inflammatory processes (Cserr et al., 
1992; Hatterer et al., 2008); however, there is negligible information as to the potential 
participation of this system on Aβ clearance. Although the brain lacks lymphatic channels, 
circulation of cerebrospinal fluid (CSF) and immune-competent cells such as dendritic and 
perivascular cells between brain (mainly perivascular spaces) and peripheral lymph nodes 
have been demonstrated (Boulton et al., 1996; Bradbury et al., 1981; Brinker et al., 1997; 
Cserr et al., 1992; Hatterer et al., 2008; Koh et al., 2005; Vega and Jonakait, 2004; Weller et 
al., 1998). It has been suggested that Aβ is present in the “interstitial cerebral fluid” (ICF) 
and that it might be drained into lymph nodes (Weller et al., 1998; Nedergaard, 2013). The 
route by which lymphatic drainage of Aβ may occur was suggested to be along basement 
membranes of cerebral capillaries and arteries (Carare, et al., 2013; Hawkes, et al., 2011). 
However, actual demonstration of Aβ in the lymph nodes has never, to our knowledge, been 
shown prior to our study. This may have been in part due to the arduous micro-dissection 
methods involved and to nuances of sample preparation for Aβ quantification.
For this investigation, we used a highly sensitive sandwich ELISA methodology (Asami-
Odaka et al., 1995; Matsubara et al., 1999; Suzuki et al., 1994) with various Aβ antibodies to 
test the hypothesis that Aβ is present in the lymph nodes and to relate its levels to those 
measured in the plasma and brain at different ages.
Methods
AD transgenic mice
We used Tg2576 transgenic mice. These mice express the 695-amino-acid isoform of human 
AβPP containing the double Lys670Asn, → Met 671→Leu mutation found in a Swedish 
family with early onset AD driven by a Syrian hamster Prnp promoter [Hsiao et al, 1996]. 
All animals were genotyped twice, at birth and after sacrifice, using a standard PCR protocol 
for genotyping as described (Hsiao et al., 1996). Mice in each experimental group were 
housed up to 4 to a cage in air-conditioned rooms at 22 °C with alternating twelve hours of 
light and darkness and fed ad libitum with AIN76A (Bethlehem, PA, USA). The Institutional 
Animal Review Board approved the use of mice for this study and national guidelines for 
humane treatment were followed.
Tissue Aβ measurement
Upon sacrifice, frontal cortex, lymph nodes and other organs (spleen, heart, lungs, intestine, 
liver) were dissected and homogenized for ELISA quantification as described (Scheuner et 
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al., 1996). Dissection of murine lymph nodes required a methodical approach for their 
identification using a dissection microscope. Upon histological confirmation, surrounding 
fibrous tissue was removed. A schematic figure showing the lymph nodes selected for the 
study is shown in Figure 3. Soluble Aβ40 and Aβ42 levels were quantified in homogenates 
from fractions extracted with Tris-saline (TS) buffer (150mg/ml). As characterized 
previously (Asami-Odaka et al., 1995; Matsubara et al., 1999; Suzuki et al., 1994), we used 
the 100,000 × g supernatants with the BNT77-BA27 or BNT77-BC05 antibodies for our 
ELISA tests to mainly quantify monomeric Aβ x-40 and x-42 species, respectively (Wako, 
Osaka, Japan). The obtained values were normalized to wet tissue weight. Microplates 
(Maxisorp White Microplate, Nunc, Rockilde, Denmark) were pre-coated with the 
antibodies for antigen capture (Takamura et al., 2011a; Takamura et al., 2011b), and 
sequentially incubated for 24 h at 4°C with 100 µl of the different samples followed by 24-
hour with horseradish-peroxidase-conjugated BA27 Fab’ fragment (anti- Aβ1–40, Wako, 
Osaka, Japan) or horseradish-peroxidase-conjugated BC05 Fab’ fragment (anti- Aβ35–43 
for Aβ42, Wako, Osaka, Japan). The conjugate was detected by chemiluminescence using 
the SuperSignal ELISA Pico substrate (Pierce, Rockford, IL, USA) on Veritas microplate 
Luminometer (Promega, Madison, WI).
Statistical analysis
Where applicable, two-tailed student t-test was used for the comparison of groups with the 
statistical software (significance at <0.05) using GraphPad Prism version 3.00 for Windows, 
(GraphPad Software, San Diego, California). Sample size (n) is listed in the figures.
Results
Detection of Aβ in lymph nodes of Tg2576 mice
Levels of monomeric soluble Aβ40, Aβ42 and its pyroglutamate (N3pE) forms were 
quantified in brain, axillary lymph nodes, cervical lymph nodes and other somatic organs 
(including heart, spleen, liver, kidney lung and intestine) of Tg2576 transgenic mice at 12 
months of age (Figure 1). Levels of monomeric Aβ40 and Aβ42 were high and readily 
detected in the brain and cervical and axillary lymph nodes and were either undetectable or 
at very low levels in the spleen and tested somatic tissues (Figure 1). N3pE- Aβ showed a 
different pattern in that its levels were substantially higher in axillary lymph nodes than in 
the brain and was very low or undetectable in other tested tissues, including cervical lymph 
nodes (Figure 1C). All forms of Aβ were low to undetectable in control lymphatic tissue 
from spleen suggesting that Aβ is not an intrinsic component produced in lymphatic tissue. 
Aβ levels were also low in peripheral organs such as the heart, liver, kidney, lung and 
intestine, strongly suggesting that the Aβ peptides found in the lymph nodes derived from 
the brain.
Time dependent change in Aβ levels in plasma and lymph nodes in Tg2576 mice
As widely reported (Hsiao et al, 1996), we observed a significant Aβ accumulation in the 
form of senile plaques in the brains of aged Tg2576 mice (data not shown). In addition, we 
observed a significant increase in saline soluble monomeric Aβ40 and Aβ42 in the aging 
brain of Tg2576 mice. The increase in Aβ40 appears to reach its peak at 12 mo (3.7 fold) 
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and remains high at 15.5 mo (3.2 fold) but Aβ42 increased steadily with age, increasing two 
fold at 12 mo and 3 fold at 15.5 mo. However, variability in Aβ40 levels was higher and the 
12-mo point only trended towards significance (p=0.07) while the 15.5 mo point was 
significant (P=0.02) (Figure 2A).
Aβ42 was significant at both points with p values of 0.023 and 0.008 at 12 and 15.5 mo. The 
brain data therefore confirm all the trends seen in previous studies with this mouse model 
(Kawarabayashi et al., 2001). To determine whether the content of monomeric Aβ in plasma 
and lymph node would change with age to reflect the raising levels of Aβ in the brain with 
age, Aβ levels were evaluated by ELISA. Using six month old brain values as baseline, we 
observed a significant increase of monomeric soluble Aβ40 (p=0.003) and Aβ42 (p=0.05) in 
the lymph nodes at 15.5 mo but did not find a significant change of either form at 12 mo. In 
contrast, plasma Aβ40 (p=0.68) showed no change and plasma Aβ42 significantly dropped 
(P=0.02) at 15.5 mo. Plasma Aβ at 6 and 12 months were not significantly different from 
each other. This reduction in plasma Aβ42 is consistent with other reports in literature 
(Kawarabayashi et al., 2001) (Figure 2).
Discussion
The molecular mechanism(s) responsible for amyloid accumulation in AD are poorly 
understood. An increase of amyloid production, a decrease of amyloid clearance or a 
combination of both may lead to abnormal amyloid accumulation in AD. Herein, we show 
for the first time that lymph nodes in a transgenic model of amyloidosis contain elevated 
levels of Aβ peptides, and that along with the blood brain barrier (BBB), they may be key 
players in the clearance of Aβ peptides from the brain. The levels of soluble monomeric 
Aβ40 and Aβ42 in lymph nodes closely mirrored the levels of the peptides over time in the 
brain. Pertaining to plasma Aβ levels, the results confirmed previous observations in Tg2576 
mice; i.e., that Aβ40 levels do not change substantially and that Aβ42 levels decrease late in 
the process while Aβ levels continue to increase in the brain (Kawarabayashi et al., 2001). A 
similar relationship was documented for Aβ levels in the CSF (Huang et al., 2012; 
Kawarabayashi et al., 2001). Therefore, these studies support the widely prevalent view that 
brain is the sink for Aβ peptides. It has been alternatively proposed that the failure to 
observe an increase in Aβ in the plasma or in the CSF reflects a steady state level reached 
over time (Huang et al., 2012; Toledo et al., 2011). On the other hand, there were two 
interesting and contrasting findings pertaining to lymphatic Aβ. First was the observation 
that Aβ42 levels in plasma at 15 months of age decreased while Aβ40 and Aβ42 continued 
to increase in the lymph nodes (Figure 2). These observations suggest two possibilities; one 
is that the lymphatic system may be more efficient than the BBB as a mechanism for 
removal of Aβ from the brain. The other is that Aβ levels continue to increase over time as a 
consequence of Aβ accumulation within lymph nodes. Either possibility requires specific 
clearance experiments for confirmation, which are outside the scope of this initial report.
We do not have an explanation at this time regarding the finding of higher Aβ levels in 
axillary lymph nodes versus cervical lymph nodes or the presence of pyroglutamate Aβ only 
in axillary lymph nodes. Pyroglutamic acid is a lactam generated between the free amino 
terminal end and the cyclizes to form a lactam. The third residue of Aβ is a glutamate and a 
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secondary cleavage that exposes this residue can form the pyroglutamate form (Mori et al., 
1992). It is possible that Aβ is converted to the pyroglutamate containing form through 
secondary cleavage during lymphatic circulation and is therefore more prevalent in the distal 
lymph node rather than the proximal cervical nodes. Such unexpected observations, 
however, are not unique to this model. Albeit rare, metastases from primary brain tumors 
have been identified in axillary lymph nodes, but not in cervical lymph nodes, of some 
human tumor cases [http://mets.getthediagnosis.org/picture/11?
sid=3233c38122c60955ff6406b93e8700a1. Accessed Jan 22, 2014]. This may underline a 
complex pattern of trafficking between the brain and lymph nodes.
The parenchyma of the CNS does not contain lymphatic channels. However, numerous 
investigations in rodents, primates and humans reveal the presence of lymphatic drainage 
from the brain into peripheral lymph nodes (for review, see (Koh et al., 2005)). Employing 
various tracers, flow from the ICF and perivascular (Virchow-Robin) spaces of the brain into 
lymph nodes has been elegantly demonstrated (Boulton et al., 1996; Brinker et al., 1997; 
Cserr et al., 1992; Vega and Jonakait, 2004). In addition to senile plaques, Aβ accumulation 
occurs also in a similar pattern (i.e., in the perivascular spaces and the ICF spaces) in AD 
(Weller et al., 1998). This pattern of accumulation has led some investigators to theorize that 
the lymphatic system may contribute to Aβ clearance (Iliff et al., 2012). Despite all of these 
prior investigations, the BBB has been studied as the primary route for Aβ clearance (Sagare 
et al; Ji et al., 2001; Shibata et al., 2000) without any reference to the role of the lymphatic 
system. To our knowledge, this study is the first to document the presence of Aβ in lymph 
nodes in support of such a mechanism of clearance. The other major study that examined 
tissue distribution of Aβ across tissues showed Aβ only in the brain although APP was 
present in multiple tissues (Kawarabayashi et al., 2001).
The potential participation of lymphatic Aβ clearance is further strengthened by additional 
recent studies reporting that murine PirB (paired immunoglobulin-like receptor B) and its 
human ortholog LilrB2 (leukocyte immunoglobulin-like receptor B2), present in human 
brain, are receptors for Aβ peptides (Kim et al., 2013). Interestingly, these receptors, which 
are members of the immunoglobulin superfamily, are found in dendritic cells and include 
cell surface antigen receptors, co-receptors and co-stimulatory molecules of the immune 
system, molecules involved in antigen presentation to lymphocytes (Cella et al., 1997).
A caveat of this investigation is the possibility that Aβ is being produced in the lymph 
nodes. However, the fact that the Prnp promoter drives expression of the transgene in the 
CNS makes such possibility extremely unlikely [for discussion of this topic see Vidal et al 
(Vidal et al., 2009). In addition, neither the quantity of Aβ in the lymph nodes nor its time 
dependent increase (which parallels Aβ in the brain) were observed in splenic lymphoid 
tissue providing evidence against lymphatic origin of Aβ (Figure 1).
In conclusion, the study of the lymphatic system in AD and in during normal aging as it 
pertains to Aβ accumulation may provide important clues to the understanding of the 
pathogenesis of this disorder and to the development of new approaches for treatment and 
prevention. We propose that different biological insults that may lead to dysfunction of the 
lymphatic system (i.e., viral infections or viral reactivation or age related immune-
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dysfunction, among several others) may potentially play an indirect (and unrecognized) role 
in the amyloid accumulation that occurs in sporadic AD. We hope that these findings 
stimulate additional research to confirm the role and extent of participation of lymphatic 
tissue in Aβ clearance from the brain.
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Research Highlights
• This is the first demonstration of Aβ in lymph nodes of an AD transgenic 
mouse model.
• There was a time dependent increase in Aβ levels in lymph nodes, mirroring 
the increase of Aβ in the brain.
• Higher levels of Aβ were detected in lymph nodes than plasma suggesting its 
closer proximity to brain Aβ.
• Lymphatic clearance is an overlooked pathway for removal of Aβ and may 
play a role in AD pathogenesis.
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FIGURE 1. Determination of Aβ in the lymph node
Levels of monomeric Aβ40 (A), Aβ42 (B), and N3pE-Aβ (C) were measured in extracts of 
brain (Br), axillary lymph node (LyA), cervical lymph node (LyC), heart (H), spleen (S), 
liver (Lv), kidney (K), lung (Lg) and Intestine (I) of Tg2576 mice at 12 months of age.
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FIGURE 2. 
2A. Age induced changes in monomeric Aβ40 and Aβ42 in brain, plasma and axillary 
lymph nodes: Monomeric Aβ in Tg2576 mice measured by ELISA assays as described in 
Methods were plotted at 6, 12 and 15 months of age along with standard deviations. P values 
compared to the six-month baseline values are indicated above the appropriate graph. Tissue 
Aβ values were adjusted to fmol/g tissue and plasma Aβ are presented as fmol/ml. In 
comparison with 6-month-old mice, brain Aβ40 (A) and Aβ42 (B) levels increased 
significantly in 15-month-old mice (P<0.01). The increasing trends were also apparent at 12 
mo with Aβ42 reaching significance (P=0.02). Axillary lymph nodes also show a parallel 
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increase in both Aβ40 (E; p<0.003) and Aβ42 (F; P<0.05) at 15 mo, but changes, if any, 
were not significant at 12 mo. Samples of cervical lymph nodes were insufficient for 
measurement and will require analysis of pooled animals in future experiments. In the 15-
month old mice, plasma Aβ40 did not show significant changes but Aβ42 levels dropped 
significantly (p=0.02).
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FIGURE 3. Schematic representation of the lymph node topographic anatomy in mice
Superficial cervical lymph nodes (LyC) and axillary lymph nodes (LyA and LyB) were 
excised and analyzed as described in Methods. Since lymph nodes in mice are very minute, 
the two axillary lymph node subgroups (axillary proper and brachial component) from both 
limbs were combined to measure Aβ.
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